Menu

Karl Deisseroth Takes Home Science’s Most Valuable Award

The Stanford University psychiatrist and neuroscientist known for his contributions to optogenetics and tissue clearing is awarded €4 million by the Fresenius Research Prize.

May 31, 2017
Jef Akst

STEVE FISCH/STANFORD SCHOOL OF MEDICINEThe 2017 Fresenius Research Prize—the most valuable award for scientific achievement—goes to Karl Deisseroth, a Stanford University professor and Howard Hughes Medical Institute investigator who helped develop the pioneering techniques of optogenetics and CLARITY tissue clearing. Deisseroth is also known for his research on the underlying neural circuitry of depression.

The award honors an individual scientist every four years by the Else Kroner-Fresenius Foundation in Germany. It comes with a cash value of €4 million ($4.47 million), and 2017 is the second time it’s been handed out. Of the total, €3.5 million will be earmarked for Deisseroth’s lab, while the remaining €500,000 are for his personal use.

While Deisseroth is in Berlin to accept the award and present a talk on his research, he emailed with The Scientist about his career and this latest achievement.

The Scientist: You’re known for so many scientific advances—optogenetics, CLARITY, neural mechanisms of depression—what do you consider your proudest achievement?

Karl Deisseroth: Well, as a psychiatrist it’s humbling to realize how far we have to go still. It’s one thing to receive this recognition for developing optogenetics and for developing hydrogel-tissue chemistry, certainly neither of which was an overnight success—each required 5-6 years of development—and quite another thing to contemplate circuit mechanisms of psychiatric diseases like depression—which will take a very much longer time to fully understand. So I would say I am gratified that we’ve come as far as we have in our work, but most proud to have helped so many other scientists do their own experiments.

TS: When did you first learn that you’d won the second-ever Fresenius Research Prize?

KD: I was just cleaning the garage and taking care of my little kids when I got the phone call. I had a cell phone reception problem but I could see the call was coming from Europe, and then there was some amusing back and forth as we tried several times to connect and talk after the first call came in. We finally got a good connection and it was very exciting; the kids thought dad was acting a little strange.

TS: Briefly, what will you be covering in your talk this week?

KD: I’ll talk about some of our very latest work, including a paper that just came out in Neuron [in] which we describe a new activity-imaging method—and its use to reveal global brain-wide dynamics that occur when a mammal takes a goal-directed action, but not in more passive states. It’s these kind of goal-directed states, in which an organism assumes effective agency over itself and its environment, that are not only of natural scientific interest but also become dysfunctional in psychiatric disease states like depression.

Read a selection of our coverage of Deisseroth’s work:

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.